[go: up one dir, main page]

WO2006125645A3 - Inhibitors of mmp-15 in cancer treatment - Google Patents

Inhibitors of mmp-15 in cancer treatment Download PDF

Info

Publication number
WO2006125645A3
WO2006125645A3 PCT/EP2006/004997 EP2006004997W WO2006125645A3 WO 2006125645 A3 WO2006125645 A3 WO 2006125645A3 EP 2006004997 W EP2006004997 W EP 2006004997W WO 2006125645 A3 WO2006125645 A3 WO 2006125645A3
Authority
WO
WIPO (PCT)
Prior art keywords
mmp
inhibitors
cancer treatment
precancerous
metalloproteinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/004997
Other languages
French (fr)
Other versions
WO2006125645A2 (en
Inventor
Axel Ullrich
Reimar Abraham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Publication of WO2006125645A2 publication Critical patent/WO2006125645A2/en
Publication of WO2006125645A3 publication Critical patent/WO2006125645A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to an agent that affects matrix- metalloproteinase 15 (MMP-15) activity and a method of diagnosing, preventing and/or treating a hyperproliferative disease such as precancerous or cancerous cell growth.
PCT/EP2006/004997 2005-05-24 2006-05-24 Inhibitors of mmp-15 in cancer treatment Ceased WO2006125645A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68377905P 2005-05-24 2005-05-24
US60/683,779 2005-05-24

Publications (2)

Publication Number Publication Date
WO2006125645A2 WO2006125645A2 (en) 2006-11-30
WO2006125645A3 true WO2006125645A3 (en) 2007-04-05

Family

ID=37452390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/004997 Ceased WO2006125645A2 (en) 2005-05-24 2006-05-24 Inhibitors of mmp-15 in cancer treatment

Country Status (1)

Country Link
WO (1) WO2006125645A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387901B1 (en) * 1999-07-06 2002-05-14 Pfizer Inc Alkyne containing metalloproteinase inhibitors
WO2002063037A2 (en) * 2001-02-02 2002-08-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for identifying functional nucleic acids
US20040010141A1 (en) * 2002-04-26 2004-01-15 Pfizer Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387901B1 (en) * 1999-07-06 2002-05-14 Pfizer Inc Alkyne containing metalloproteinase inhibitors
WO2002063037A2 (en) * 2001-02-02 2002-08-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for identifying functional nucleic acids
US20040010141A1 (en) * 2002-04-26 2004-01-15 Pfizer Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OHIRA T ET AL: "Up-regulated gene expression of angiogenesis factors in post-chemotherapeutic lungcancer tissues determined by cDNA macroarray", ONCOLOGY REPORTS, NATIONAL HELLENIC RESEARCH FOUNDATION, ATHENS, GR, vol. 9, April 2002 (2002-04-01), pages 723 - 728, XP002995097, ISSN: 1021-335X *

Also Published As

Publication number Publication date
WO2006125645A2 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
WO2004080430A3 (en) Methods of improving skin quality
WO2007140002A3 (en) Method for treating non-hodgkin's lymphoma
WO2004008147A3 (en) Diagnosis and prevention of cancer cell invasion
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2006133022A3 (en) Compositions and methods for decreasing microrna expression for the treatment of neoplasia
WO2006045119A3 (en) Improved inhibitors for the soluble epoxide hydrolase
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2006138418A3 (en) Improvement of cognitive performance with sirtuin activators
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2006015263A3 (en) Lonidamine analogs
WO2006083328A3 (en) Biologically active surfaces and methods of their use
WO2004089296A3 (en) Improved inhibitors for the soluble epoxide hydrolase
WO2004056307A3 (en) Disease treatment via antimicrobial peptide inhibitors
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
AU2003300368A8 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2003087831A3 (en) Proteins involved in breast cancer
WO2005123116A3 (en) Compositions and methods for treating or preventing oxalate-related disease
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2004058158A3 (en) Treatment of metastatic cancer with the b-subunit of shiga toxin
WO2006113790A3 (en) Compositions and methods for the treatment of cancer
IL165052A0 (en) Medium for contrast enhancement or convenience forultrasonic, endoscopic and other medical examinat ions
WO2004087066A3 (en) Hif-1 inhibitors
WO2005060960A3 (en) Use of histamine to treat bone disease
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06753867

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06753867

Country of ref document: EP

Kind code of ref document: A2